ReviewViruses2020
Hepatitis C Virus and Hepatitis B Virus Co-Infection.
Review in Viruses, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 48 citations in OpenAlex.
- Viral persistence and immune dysfunction in chronic hepatitis B: Mechanisms of post-treatment antigen asynchrony.iScience · 2026Review
- Seroepidemiological Prevalence of Hepatitis B and C Virus Coinfection: A Large-Scale Retrospective Cohort Study in Istanbul.Diagnostics (Basel, Switzerland) · 2026Article
- Evaluation of the Safety and Efficacy of SOF/VEL Treatment and Pre-treatment of TAF in Patients with Chronic Hepatitis B Virus/Hepatitis C Virus Coinfection: A Multicenter Study.Journal of clinical and translational hepatology · 2026Article
- Treatment strategies for patients with hepatitis B virus infection coexisting with hepatitis C virus or metabolic dysfunction-associated steatotic liver disease.Clinical and molecular hepatology · 2026Review
- Prediction of Treatment Response in Hepatitis B and Hepatitis C Coinfected Patients Using a Leakage-Proof, Internally Validated Logistic Regression Pipeline.Advances in virology · 2026Article
- Harmonic analysis of radial pulse in traditional Chinese medicine: physiological alterations associated with hepatitis B and hepatitis C infections.Frontiers in medicine · 2026Article
- HBV Dominance Is Associated With a Distinct Inflammatory Milieu in HBV/HCV Coinfection.Journal of viral hepatitis · 2025Article
- Demographic and Clinical Characteristics of Patients With Hepatitis C and Hepatitis B Co-Infection, Georgia, 2017-2023.Journal of viral hepatitis · 2025Article
- Immune responses underpinning acute co-infections with unrelated viruses: timing and location matter.International immunology · 2025Review
- HCV and HBV genotypes: vital in the progression of HCV/ HBV co-infection.BMC gastroenterology · 2025Article
- [Research progress on hepatitis B combined with C and its treatment].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Review
- Hepatitis B Virus DNA and RNA Persist in Liver After Serologic Recovery in Persons With Hepatitis C Virus.The Journal of infectious diseases · 2024Article
- One-step, rapid, nanoparticle-based biosensor platform for the simultaneous identification of hepatitis B virus and hepatitis C virus in clinical applications.BMC microbiology · 2024Article
- HBCVTr: an end-to-end transformer with a deep neural network hybrid model for anti-HBV and HCV activity predictor from SMILES.Scientific reports · 2024Article
- Hepatitis B Immunization Status in Children with Chronic Kidney Disease: Experience at a Single Center, Egypt.Journal of clinical medicine · 2023Article
- Case report: Unusual viral evolutions following antiviral therapies in a patient with concurrent hepatitis B virus and hepatitis C virus infection.Frontiers in medicine · 2023Article
- Impact ofFrontiers in microbiology · 2023Article
- [Mechanism and clinical significance of HBV reactivation after anti-HCV therapy].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022Review
- Hepatitis C Virus Reactivation in Anti-HCV Antibody-Positive Patients with Chronic Hepatitis B Following Anti-HBV Therapies.Viruses · 2022Article
- Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection.World journal of hepatology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C virus (HCV) and hepatitis B virus (HBV) co-infection can be encountered in either virus endemic countries. Co-infection can also be found in populations at risk of parenteral transmission. Previous studies demonstrated a high risk of liver disease progression in patients with HCV/HBV co-infection; thus, they should be treated aggressively. Previous evidence recommended therapy combining peginterferon (pegIFN) alfa and ribavirin for co-infected patients with positive HCV RNA. Recent trials further advise using direct-acting antivirals (DAAs) for the clearance of HCV in the co-infected patients. Reactivation of HBV has been observed in patients post-intervention, with higher risks and earlier onset in those having had HCV cured by DAA- versus pegIFN-based therapy. The mechanism of HBV reactivation is an interesting but unsolved puzzle. Our recent study revealed that in vitro HBV replication was suppressed by HCV co-infection; HBV suppression was attenuated when interferon signaling was blocked. In vivo, the HBV viremia, initially suppressed by the presence of HCV super-infection, rebounded following HCV clearance by DAA treatment and was accompanied by a reduced hepatic interferon response. In summary, major achievements in the treatment of HCV/HBV co-infection have been accomplished over the past 20 years. Future clinical trials should address measures to reduce or prevent HBV reactivation post HCV cure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.